Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis.

Breast Cancer Res TreatSep 28, 2026 (epub)
Clinical ResearchOncology (Medical)Medical GeneticsPathology (Anatomic & Clinical)Open access

Cæcilie Ottosen, Ea Kragelund, Mette Abildgaard Pedersen et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of circulating tumour DNA (ctDNA) in predicting progression-free survival (PFS) and overall survival (OS) in patients with advanced breast cancer (ABC). The analysis included 64 studies, revealing that elevated baseline ctDNA levels were significantly associated with shorter PFS (pooled HR = 2.0) and OS (pooled HR = 2.6).

Key findings

  • Elevated baseline ctDNA levels were associated with shorter PFS (pooled HR = 2.0; 95% CI: 1.8-2.3).
  • Elevated baseline ctDNA levels were associated with shorter OS (pooled HR = 2.6; 95% CI: 2.1-3.3).
  • Unfavourable changes in ctDNA levels were linked to reduced PFS (pooled HR = 2.5; 95% CI: 1.9-3.4).
  • Unfavourable changes in ctDNA levels were associated with reduced OS (pooled HR = 2.4; 95% CI: 1.5-3.8).

Why it matters

The findings suggest that ctDNA can serve as a valuable biomarker for assessing prognosis in advanced breast cancer, potentially guiding treatment decisions and monitoring strategies beyond traditional imaging methods.

Source

PubMed · PMID 42804029Free full text on PubMed Central

Published in Breast Cancer Res Treat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.